> ## Content Index
> Fetch the complete content index at: https://bioweek.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Why Lyrfigtu's FGFR2 Selectivity Matters More Than Its 46% Response Rate
- URL: https://bioweek.com/why-lyrfigtus-fgfr2-selectivity-matters-more-than-its-46-response-rate/
- Published: 2026-09-24T05:04:51.000Z
- Updated: 2026-09-24T05:04:51.000Z
- Description: FDA cleared lirafugratinib (Lyrfigtu) for FGFR2-altered cholangiocarcinoma after ReFocus posted a 46% response rate. The clinical argument is FGFR1 sparing. The cost is months of mandatory retinal monitoring.
- Author: BioWeek
- Tags: Pipeline, Science, Markets

On September 23, 2026, the FDA [approved](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lirafugratinib-previously-treated-unresectable-locally-advanced-or-metastatic?ref=bioweek.com) lirafugratinib (Lyrfigtu, Elevar Therapeutics) for adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement. Reviewed under Real-Time Oncology Review and an Assessment Aid, the oral kinase inhibitor is dosed at 70 mg once daily.

In 116 FGFR inhibitor-naive patients on the pivotal ReFocus trial (NCT04526106) who had progressed on prior systemic therapy, Elevar [reported](https://www.globenewswire.com/news-release/2026/09/23/3367897/0/en/elevar-therapeutics-announces-fda-approval-of-lyrfigtu-lirafugratinib-as-second-line-cholangiocarcinoma-with-fgfr2-fusion-or-other-rearrangement-treatment-option.html?ref=bioweek.com) a confirmed objective response rate of 46% (95% CI: 36% to 55%) per independent review. Median duration of response reached 11.8 months (95% CI: 7.5 to 13.0), while median progression-free survival reached 11.3 months (95% CI: 9.2 to 14.8). Those metrics sit slightly above established pan-FGFR labels. Yet response rate alone does not explain why the drug matters. The sharper story is chemical selectivity.

### A covalent FGFR2 bet over pan-FGFR inhibition

Lirafugratinib originated as RLY-4008 at Relay Therapeutics, designed on the company's Dynamo computational platform. Cancer Discovery [published](https://doi.org/10.1158/2159-8290.cd-23-0475?ref=bioweek.com) its defining profile: a covalent small molecule selective for FGFR2, showing more than 250-fold selectivity over FGFR1, 80-fold over FGFR3, and 5,000-fold over FGFR4\. The drug also retained preclinical activity against acquired gatekeeper and hinge mutations that defeat first-generation agents, including FGFR2 V564F/L/I and N549K/D.

That molecular profile forms the clinical argument. Pemigatinib (Incyte's Pemazyre) demonstrated a [final](https://doi.org/10.1016/j.esmoop.2024.103488?ref=bioweek.com) FIGHT-202 objective response rate of 37.0%, median response duration of 9.1 months, and median PFS of 7.0 months. Futibatinib (Taiho's Lytgobi) in the FOENIX-CCA2 [trial](https://doi.org/10.1056/nejmoa2206834?ref=bioweek.com) reached a 42% ORR, median response duration of 9.7 months, and median PFS of 9.0 months. Cross-trial comparisons carry caveats, but Lyrfigtu leads the class on paper. Even so, few oncologists would switch based on single-digit response gains alone.

### Escaping the FGFR1 hyperphosphatemia treadmill

The practical differentiator is phosphate handling. First-generation pan-FGFR inhibitors hit FGFR1, disrupting FGF23-mediated renal phosphate excretion and causing dose-limiting hyperphosphatemia. In FIGHT-202, any-grade hyperphosphatemia hit 58.5% of patients. In FOENIX-CCA2, grade 3 hyperphosphatemia reached 30%. By sparing FGFR1, lirafugratinib reduced hyperphosphatemia incidence to 21%. Only one patient (0.3%) required a dose interruption for phosphate elevation, and none discontinued permanently.

For oncology clinics, this provides immediate operational relief. Routine phosphate binders, dietary restrictions, and frequent mid-cycle serum monitoring have burdened the FGFR workflow since pemigatinib entered practice. A daily oral therapy that avoids that metabolic burden simplifies management, provided it does not introduce an equal liability elsewhere.

### The ocular surveillance trade-off

Lirafugratinib introduces its own clinical burden. Across 385 patients in the broader safety cohort, retinal pigment epithelial detachment (RPED) occurred in 31%, with 1.8% experiencing grade 3 events. Median time to first onset was 57 days. RPED triggered dose interruptions in 15% of patients and dose reductions in 10%. Blurred vision occurred in 18%, dry eye in 38%, and corneal toxicity in 11%.

The FDA label consequently mandates comprehensive ophthalmological exams, including optical coherence tomography (OCT) of the macula, at baseline, every 2 months for the first 13 months, and every 4 months thereafter. Epithelial toxicities were also widespread: nail toxicity, hand-foot syndrome, stomatitis, and alopecia each occurred in more than 20% of patients, with serious adverse reactions reaching 32%. Oncologists are effectively trading a metabolic toxicity managed with binders and labs for an on-target ocular toxicity requiring specialized ophthalmology coordination and frequent retinal imaging.

### Commercial reality in a rare patient population

Cholangiocarcinoma is diagnosed in roughly 8,000 Americans annually. FGFR2 fusions or rearrangements occur in about 10% to 15% of intrahepatic cases, creating a narrow commercial target in the second-line setting. Relay [licensed](https://ir.relaytx.com/news-releases/news-release-details/relay-therapeutics-and-elevar-therapeutics-announce-exclusive?ref=bioweek.com) global rights to Elevar, a subsidiary of South Korea's HLB Co., in December 2024 to focus internal capital on its clinical PI3K-alpha inhibitor, RLY-2608\. Relay remains eligible for up to $75 million in upfront and regulatory milestones, $425 million in commercial milestones, and tiered royalties in the low teens.

Elevar must now launch into a niche already contested by two established pan-FGFR drugs. Lyrfigtu delivers the cleanest FGFR2 selectivity to reach market, paired with broader coverage against known resistance mutations. Its commercial adoption will depend less on whether its 46% response rate looks superior on slides, and more on whether community cancer centers embrace intensive retinal monitoring to leave hyperphosphatemia behind.